Product
ATG-010
Aliases
Selinexor
4 clinical trials
4 indications
Indication
Diffuse Large B-cell LymphomaIndication
Indolent Non-Hodgkin LymphomaIndication
Relapse/Refractory Multiple MyelomaClinical trial
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adult Patients With Relapsed/Refractory DLBCL and iNHL Who Are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (ASCT)Status: Recruiting, Estimated PCD: 2025-03-07
Clinical trial
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
An Open Label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)Status: Terminated, Estimated PCD: 2023-02-06
Clinical trial
An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome InhibitorStatus: Completed, Estimated PCD: 2022-02-25